28
total announcements
543245.BO · 15 min delayed
Gland Pharma Ltd
Gland Pharma Ltd has announced the notice of its 48th Annual General Meeting (AGM) to be held on August 25, 2022, at 11:00 AM through video conferencing or other audio-visual means. The AGM will consider the financial year ended March 31, 2022, and other business.
Gland Pharma Ltd
Gland Pharma Ltd has allotted 66,997 equity shares under the Employee Stock Option Scheme (ESOS) to 88 employees at a price of Rs. 11 per share, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Gland Pharma Ltd
Gland Pharma Ltd has announced the grant of stock options under the Gland Pharma Employee Stock Option Scheme, 2025, to its employees.
Gland Pharma Ltd
Gland Pharma receives approval for Suggamadex Injection from the United States FDA and Drug Administration, and has successfully launched the product on the market.
Gland Pharma Ltd
Gland Pharma Ltd has announced its annual general meeting (AGM) scheduled for August 25, 2022, at 11:00 AM through video conferencing or audio-visual means. The company has made necessary provisions in its act and rules for the AGM, and the list of obligations and disclosure requirements under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, have been complied with.
Gland Pharma Ltd
Gland Pharma Ltd has announced its Q1FY27 earnings call intimation, indicating that the company will be hosting an analyst/investor meet on July 22, 2023, to discuss its quarterly results.
Gland Pharma Ltd
Gland Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 to consider and approve Unaudited Standalone and Consolidated Financial Results for the Quarter Ended June 30, 2026.
Gland Pharma Ltd
Gland Pharma Ltd has intimated the stock exchanges about a scheduled analyst/institutional investor meeting. The company will be conducting a one-on-one meeting with Ambit PMS on June 25, 2026. This intimation is made in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The schedule remains subject to change due to exigencies from the investor, analyst, or the company.